Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Growth Is Accelerating As Industry Transformation Continues
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Analysis: What Growth Is Expected Over The Forecast Period?
The market for treating chronic obstructive pulmonary disease (COPD) has shown robust expansion in recent years. Valued at $21.73 billion in 2025, it is expected to reach $22.9 billion by 2026, achieving a compound annual growth rate (CAGR) of 5.4%. Several key factors have driven this growth over the historical period, including elevated rates of smoking, an expanding elderly demographic, rising concentrations of air pollution, greater occupational contact with dust, and enhanced recognition of COPD as a health concern.
The market for chronic obstructive pulmonary disease (COPD) treatments is projected to experience significant expansion over the coming years. By 2030, its value is anticipated to reach $29.13 billion, reflecting a compound annual growth rate (CAGR) of 6.2%. This upward trajectory during the forecast period is driven by factors such as the increased use of combination therapies, the expansion of home-based care models, higher healthcare spending, improved rates of COPD diagnosis, and advancements in inhaled drug delivery systems. Key developments shaping this period include a greater uptake of triple combination inhaler therapies, a notable movement toward managing COPD at home, a heightened emphasis on early detection and screening, the growth of affordable generic COPD medications, and the broader application of non-pharmacological approaches like pulmonary rehabilitation.
Download A Free Sample Report For Comprehensive Market Insights:
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Demand Drivers: What Is Fueling Industry Growth?
The growing incidence of smoking is anticipated to drive expansion in the chronic obstructive pulmonary disease (COPD) treatment market moving forward. Smoking involves the inhalation of smoke, often from burning materials like tobacco, through the mouth. COPD treatment is commonly chosen by smokers to promote better breathing, enhance life quality, decrease exacerbation episodes, boost exercise capacity, extend survival, and support mental well-being. For example, in July 2023, the World Health Organization, an intergovernmental body based in Switzerland, reported that tobacco claims over 8 million lives annually, including 1.3 million non-smokers exposed to second-hand smoke. Consequently, the rising prevalence of smoking is fueling growth in the chronic obstructive pulmonary disease (COPD) treatment market.
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Segment Landscape: Which Areas Lead Market Development?
The chronic obstructive pulmonary disease (copd) treatment market covered in this report is segmented –
1) By Drug Class: Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics, Other Drug Classes
2) By Type: Chronic Bronchitis, Emphysema
3) By End-User: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Combination Therapy: Long-Acting Beta-Agonists (LABA) + Inhaled Corticosteroids (ICS), Long-Acting Muscarinic Antagonists (LAMA) + LABA, Triple Therapy (LAMA + LABA + ICS)
2) By Bronchodilators: Short-Acting Beta-Agonists (SABA), Long-Acting Beta-Agonists (LABA), Long-Acting Muscarinic Antagonists (LAMA)
3) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Injectable Corticosteroids
4) By Phosphodiesterase Type 4 Inhibitor: Roflumilast, Other PDE4 Inhibitors
5) By Mucokinetics: Expectorants, Mucolytics
6) By Other Drug Classes: Antibiotics, Antivirals, Antifungal Agents
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Innovation Trends: Which Developments Are Transforming The Industry?
Major players in the chronic obstructive pulmonary disease (COPD) treatment market are turning their attention to groundbreaking products like Vilfuro-G as a strategy to boost their market revenues. Vilfuro-G has achieved a world first as a fixed-dose triple combination medication (FDC) specifically formulated for the effective management of chronic obstructive pulmonary disease (COPD). For example, Lupin Limited, a pharmaceutical company headquartered in India, launched Vilfuro-G in November 2023. This product is available in a single fixed dose strength, with a once-daily administration schedule recommended. The rollout of Vilfuro-G is expected to bring significant improvements to the quality of life for COPD patients and to expand Lupin’s portfolio of respiratory treatments, underscoring the firm’s commitment to delivering innovative therapeutic options for both patients and healthcare providers. Vilfuro-G stands out as the only fixed-dose combination (FDC) that uniquely integrates glycopyrronium bromide, vilanterol, and fluticasone furoate for the sustained management of moderate to severe COPD.
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Industry Leaders And Market Competition
Major companies operating in the chronic obstructive pulmonary disease (copd) treatment market are Almirall S.A., AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A, Sunovion Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Sanofi S.A, Theravance Biopharma Inc., Verona Pharmaceuticals plc, Pfizer Inc., Mylan N.V., Orion Corporation, Cipla Limited, Glenmark Pharmaceuticals Limited, Biocon Limited, Lupin Limited, Mundipharma International Limited
Access The Complete Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Report:
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the chronic obstructive pulmonary disease (COPD) treatment market in 2025. Asia-Pacific is expected to be the global chronic obstructive pulmonary disease (COPD) treatment market report during the fastest-growing region in the forecast period. The regions covered in the chronic obstructive pulmonary disease (copd) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
